GO-203-2c
/ XYone Therap
- LARVOL DELTA
Home
Next
Prev
1 to 12
Of
12
Go to page
1
January 24, 2025
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1/2 | N=33 | Active, not recruiting | Sponsor: Beth Israel Deaconess Medical Center | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Sep 2024 ➔ Sep 2025
Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology
June 11, 2024
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1/2 | N=33 | Active, not recruiting | Sponsor: Beth Israel Deaconess Medical Center | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Jul 2023 ➔ Sep 2024
Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology
January 10, 2023
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1/2 | N=33 | Active, not recruiting | Sponsor: Dana-Farber Cancer Institute | Trial completion date: Jul 2023 ➔ Dec 2023 | Trial primary completion date: Dec 2022 ➔ Jul 2023
Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • MUC1
January 26, 2022
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1/2 | N=33 | Active, not recruiting | Sponsor: Dana-Farber Cancer Institute | Trial completion date: Jul 2022 ➔ Jul 2023 | Trial primary completion date: Dec 2021 ➔ Dec 2022
Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • MUC1
August 18, 2021
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1/2; N=33; Active, not recruiting; Sponsor: Dana-Farber Cancer Institute; Trial completion date: Jul 2021 ➔ Jul 2022; Trial primary completion date: Dec 2020 ➔ Dec 2021
Clinical • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • MUC1
April 23, 2021
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1/2; N=33; Active, not recruiting; Sponsor: Dana-Farber Cancer Institute; Trial primary completion date: Jul 2020 ➔ Dec 2020
Clinical • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • MUC1
December 22, 2020
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1/2; N=33; Active, not recruiting; Sponsor: Dana-Farber Cancer Institute; Trial primary completion date: Nov 2019 ➔ Jul 2020
Clinical • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • MUC1
February 24, 2017
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1/2; N=53; Recruiting; Sponsor: Dana-Farber Cancer Institute; Trial primary completion date: Oct 2017 ➔ Oct 2018
Clinical • P1/2 data • Trial primary completion date
April 20, 2019
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1/2; N=33; Active, not recruiting; Sponsor: Dana-Farber Cancer Institute; Recruiting ➔ Active, not recruiting; N=53 ➔ 33
Clinical • Enrollment change • Enrollment closed
July 30, 2014
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1/2; N=53; Not yet recruiting; Sponsor: Dana-Farber Cancer Institute
Clinical • New P1/2 trial • P1/2 data
August 25, 2018
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1/2; N=53; Recruiting; Sponsor: Dana-Farber Cancer Institute; Trial primary completion date: Oct 2018 ➔ Nov 2019
Clinical • Trial primary completion date
September 16, 2014
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1/2; N=53; Recruiting; Sponsor: Dana-Farber Cancer Institute; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • P1/2 data
1 to 12
Of
12
Go to page
1